HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adding Zarbee's, J&J Gains Natural Market Footprint, Claims Credibility

This article was originally published in The Rose Sheet

Executive Summary

Zarbee's Naturals vitamin, mineral and dietary supplement products were launched in 2008 by a physician interested in offering non-drug alternative remedies for children and adults for indications such as cough and cold, sore throat, immune support, sleep and digestive health. J&J on the other hand, has been challenged in class action litigation about natural claims it's used on some of its Aveeno and Neutgrogena skin care product labels.

You may also be interested in...

NAD Nixes Wink Cough Claims In J&J's Second Challenge Against Firm Headed By Founder Of Its Zarbee's Business

For second time in a week, Council of Better Business Bureaus division published results of review of ad claims for Wink products on a J&J challenge. NAD attorneys recommended Wink discontinue two claims for its cough syrup dietary supplement, “soothing relief for coughs” and “soothes coughs and irritated throats naturally,” but said its claim “zinc and elderberry combine to form the ultimate immune system support” did not communicate a message of superior performance.

Wink's Ad Claims For Children's Melatonin Fail In Review From J&J Challenge

NAD advises Wink Naturals to discontinue online and social media claims that its melatonin-containing supplements for children are “appropriately dosed for children” and their delivery method is superior to competing products.

Rapid Release Gels, Arthritis Formulation Put Tylenol In US OTC Analgesic Lead

Tylenol brand consumption grows 10% on sales of Rapid Release Gel and Tylenol Arthritis, reaching top spot among analgesic products in the US, J&J says. Retailers' inventory builds as a result of prior-year supply constraints driven by Hurricane Maria also helped drive growth.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts